DexCom Management

Management criteria checks 3/4

DexCom's CEO is Kevin Sayer, appointed in Jun 2011, has a tenure of 12.92 years. total yearly compensation is $15.71M, comprised of 7% salary and 93% bonuses, including company stock and options. directly owns 0.044% of the company’s shares, worth €20.81M. The average tenure of the management team and the board of directors is 2.7 years and 9.5 years respectively.

Key information

Kevin Sayer

Chief executive officer

US$15.7m

Total compensation

CEO salary percentage	7.0%
CEO tenure	12.9yrs
CEO ownership	0.04%
Management average tenure	2.7yrs
Board average tenure	9.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Kevin Sayer's remuneration changed compared to DexCom's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	US$639m
Dec 31 2023	US$16m	US$1m	US$542m
Sep 30 2023	n/a	n/a	US$377m
Jun 30 2023	n/a	n/a	US$358m
Mar 31 2023	n/a	n/a	US$293m
Dec 31 2022	US$15m	US$953k	US$341m
Sep 30 2022	n/a	n/a	US$244m
Jun 30 2022	n/a	n/a	US$230m
Mar 31 2022	n/a	n/a	US$258m
Dec 31 2021	US$12m	US$900k	US$217m
Sep 30 2021	n/a	n/a	US$577m
Jun 30 2021	n/a	n/a	US$562m
Mar 31 2021	n/a	n/a	US$530m
Dec 31 2020	US$14m	US$800k	US$550m
Sep 30 2020	n/a	n/a	US$231m
Jun 30 2020	n/a	n/a	US$205m
Mar 31 2020	n/a	n/a	US$148m
Dec 31 2019	US$10m	US$691k	US$101m
Sep 30 2019	n/a	n/a	-US$171m
Jun 30 2019	n/a	n/a	-US$170m
Mar 31 2019	n/a	n/a	-US$130m
Dec 31 2018	US$10m	US$601k	-US$127m
Sep 30 2018	n/a	n/a	US$43m
Jun 30 2018	n/a	n/a	-US$5m
Mar 31 2018	n/a	n/a	-US$33m
Dec 31 2017	US$8m	US$546k	-US$50m

Compensation vs Market: Kevin's total compensation ($USD15.71M) is above average for companies of similar size in the German market ($USD5.55M).

Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.

CEO

Kevin Sayer (65 yo)

12.9yrs

Tenure

US$15,712,244

Compensation

Mr. Kevin Ronald Sayer has been Executive Chairman of DexCom, Inc. since July 30, 2018. Mr. Sayer has been the Chief Executive Officer of DexCom, Inc. since January 5, 2015 and as its President since June...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Kevin Sayer	Executive Chairman	12.9yrs	US$15.71m	0.044% $ 20.8m
Jereme Sylvain	Executive VP	4.2yrs	US$4.25m	0.0081% $ 3.8m
Jacob Leach	Executive VP & COO	1.8yrs	US$4.94m	0.065% $ 30.7m
Michael Brown	Executive VP & Chief Legal Officer	2.3yrs	US$4.34m	0.0021% $ 1.0m
Teri Lawver	Executive VP & Chief Commercial Officer	1.3yrs	US$6.53m	0.0016% $ 783.5k
Girish Naganathan	Executive VP & CTO	1.6yrs	US$4.05m	0.0014% $ 641.0k
Shelly Selvaraj	Senior VP & Chief Information Officer	2.7yrs	no data	0.0065% $ 3.1m
Sean Christensen	Director of Corporate Affairs & Head of Investor Relations	no data	no data	no data
Matthew Dolan	Executive Vice President of Strategy	3.2yrs	no data	0.00058% $ 275.4k
Leverne Marsh	Executive Vice President of Marketing	less than a year	no data	no data
Sadie Stern	Executive VP & Chief Human Resources Officer	3.7yrs	no data	0.0056% $ 2.7m
Steven Pacelli	Executive VP & MD of Dexcom Ventures	3.1yrs	US$3.02m	0.022% $ 10.2m

2.7yrs

Average Tenure

49.5yo

Average Age

Experienced Management: DC4's management team is considered experienced (2.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Kevin Sayer	Executive Chairman	16.5yrs	US$15.71m	0.044% $ 20.8m
Mark Foletta	Lead Independent Director	9.5yrs	US$393.51k	0.015% $ 7.1m
Steven Altman	Independent Director	10.5yrs	US$343.40k	0.013% $ 6.3m
Eric Topol	Independent Director	14.8yrs	US$346.49k	0.094% $ 44.8m
Nicholas Augustinos	Independent Director	14.5yrs	US$362.21k	0.0086% $ 4.1m
Bridgette Heller	Independent Director	4.7yrs	US$346.49k	0.0052% $ 2.5m
Barbara Kahn	Independent Director	13.1yrs	US$348.40k	0.0057% $ 2.7m
Kyle Malady	Independent Director	3.6yrs	US$343.40k	0.0032% $ 1.5m
Karen Dahut	Independent Director	3.8yrs	US$345.90k	0.0031% $ 1.5m
Richard Collins	Independent Director	7.2yrs	US$345.90k	0.0092% $ 4.3m
Rimma Driscoll	Independent Director	less than a year	US$404.72k	0% $ 0

9.5yrs

Average Tenure

62yo

Average Age

Experienced Board: DC4's board of directors are considered experienced (9.5 years average tenure).

DexCom Management

Management criteria checks 3/4

Key information

Recent management updates

DexCom, Inc., Annual General Meeting, May 22, 2024

DexCom, Inc., Annual General Meeting, May 22, 2024

Executive Chairman recently sold €3.7m worth of stock

Executive Chairman recently sold €4.2m worth of stock

Insufficient new directors

DexCom, Inc. Announces Appointment of Rimma Driscoll to Its Board of Directors

Recent updates

DexCom, Inc. Provides Earnings Guidance for the Year 2024

First quarter 2024 earnings released: EPS: US$0.38 (vs US$0.13 in 1Q 2023)

DexCom, Inc., Annual General Meeting, May 22, 2024

DexCom, Inc., Annual General Meeting, May 22, 2024

New minor risk - Shareholder dilution

DexCom, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Executive Chairman recently sold €3.7m worth of stock

DexCom, Inc. Announces the FDA Clears Stelo by Dexcom – the First Glucose Biosensor

Now 21% undervalued

Full year 2023 earnings released: EPS: US$1.40 (vs US$0.88 in FY 2022)

DexCom, Inc. Reiterates Revenue Guidance for the Fiscal Year 2024

DexCom, Inc. Launches Dexcom One+ Bringing Powerful, New Diabetes Management Technology to More People

New minor risk - Insider selling

Executive Chairman recently sold €4.2m worth of stock

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects with the t:Slim X2™ Insulin Pump by Tandem Diabetes Care in Countries Across Europe and in South Africa

DexCom, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Dexcom, Inc. Provides Revenue Guidance for the Full Year of 2024

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects with the Tandem t:slim X2 Insulin Pump

Insufficient new directors

DexCom, Inc. (NasdaqGS:DXCM) announces an Equity Buyback for $500 million worth of its shares.

Third quarter 2023 earnings released: EPS: US$0.31 (vs US$0.26 in 3Q 2022)

New minor risk - Share price stability

Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring with New Clinical Data Presented at EASD

DexCom, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Now 21% undervalued after recent price drop

DexCom, Inc Announces the Availability of Its Dexcom One Real-Time CGM Sensor Via Reimbursement, in France

DexCom, Inc. Announces Appointment of Rimma Driscoll to Its Board of Directors

DexCom, Inc. Increases Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.30 (vs US$0.13 in 2Q 2022)

DexCom, Inc. to Report Q2, 2023 Results on Jul 27, 2023

Dexcom, Inc. Receives Health Canada Approval: Next-Generation Continuous Glucose Monitoring System with Unmatched Accuracy Coming to Canadians

DexCom, Inc. Updates Earnings Guidance for the Year 2025

First quarter 2023 earnings released: EPS: US$0.13 (vs US$0.25 in 1Q 2022)

DexCom, Inc. Reiterates Revenue Guidance for the Fiscal Year 2023

Full year 2022 earnings released: EPS: US$0.88 (vs US$0.40 in FY 2021)

Executive Chairman recently sold €4.5m worth of stock

Dexcom, Inc.'s G6 Real-Time CGM System Now Available to All Clients With Type 1 Diabetes Covered Under the Non-Insured Health Benefits Program

DexCom, Inc. to Report Q4, 2022 Results on Feb 09, 2023

Dexcom, Inc. Receives FDA Clearance of Next-Generation Dexcom G7 Continuous Glucose Monitoring System

Third quarter 2022 earnings released: EPS: US$0.26 (vs US$0.18 in 3Q 2021)

DexCom, Inc. Provides Earnings Guidance for the Year 2022

DexCom, Inc. Announces the Launch of Dexcom U

DexCom, Inc. Announces Launch of Dexcom G7 in the United Kingdom, Ireland, Germany, Austria and Hong Kong – Initiating Global Rollout of World’s Most Powerful Continuous Glucose Monitoring System

DexCom, Inc. to Report Q3, 2022 Results on Oct 27, 2022

DexCom, Inc. Promotes Jacob S. Leach to Chief Operating Officer

DexCom, Inc. Announces One Real-Time Continuous Glucose Monitoring (rt-CGM) System Available on Prescription in the UK

Second quarter 2022 earnings released: EPS: US$0.13 (vs US$0.20 in 2Q 2021)

DexCom, Inc. (NasdaqGS:DXCM) announces an Equity Buyback for $700 million worth of its shares.

DexCom, Inc. Revises Earnings Guidance for the Full Year 2022

DexCom, Inc. Announces Resignation of Chad M. Patterson as Executive Vice President, Global Marketing, Effective July 15, 2022

DexCom, Inc. to Report Q2, 2022 Results on Jul 28, 2022

Dexcom Says Not in Active Merger Talks

Dexcom Reportedly in Talks to Acquire Insulet

First quarter 2022 earnings released: EPS: US$1.00 (vs US$0.42 in 1Q 2021)

DexCom, Inc. Showcases Expanded CGM Portfolio at International ATTD Conference

Dexcom Announces Dexcom ONE, the Newest Real-Time Continuous Glucose Monitoring System, to Its Range of Scan-Free and Fingerprick†-Free Devices

DexCom, Inc. to Report Q1, 2022 Results on Apr 28, 2022

DexCom, Inc. Reiterates Earnings Guidance for the Fiscal Year 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Executive Chairman recently sold €7.6m worth of stock

Dexcom, Inc. Reports Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Fiscal Year Ended December 31, 2021; Revenue Guidance for the Fiscal Year 2022

Insider recently sold €485k worth of stock

Third quarter 2021 earnings released: EPS US$0.73 (vs US$0.75 in 3Q 2020)

Dexcom G6 Continuous Glucose Monitoring System Now Covered in Manitoba for Young People with Type 1 Diabetes

Chief Operating Officer Quentin Blackford has left the company

Dexcom, Inc. Announces Non-insured Health Benefits Program Covers Dexcom G6 Continuous Glucose Monitoring System for Children and Adolescents on Intensive Insulin Therapy

Chief Operating Officer recently sold €4.3m worth of stock

Second quarter 2021 earnings released: EPS US$0.65 (vs US$0.49 in 2Q 2020)

FDA Clears DexCom, Inc.'s Real-Time APIs for Third-Party Apps and Devices